Search Share Prices
Omega reaches new milestone with VISITECT CD4
Medical diagnostics company Omega Diagnostics updated the market on its 'VISITECT CD4' development programme on Monday, after its recently-held design review meeting for the test designed to identify advanced HIV disease.
The AIM-traded firm confirmed that results from feasibility testing showed "acceptable performance" against design goals.
As a result, Omega had now progressed into a formal optimisation phase within its design control programme.
"I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications," said Omega CEO Colin King.
"This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market.
"I look forward to making further announcements as we bring this product to market."